ALB and non-small cell lung carcinoma: Owing to its favorable clinical efficacy and safety profile, nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic breast cancer, non-small cell lung cancer (NSCLC), and other malignancies.